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Considering that the homozygous CNDP1 (CTG)5 genotype aﬀords protection against diabetic nephropathy (DN) in female
patients with type 2 diabetes, this study assessed if this association remains gender-speciﬁc when applying clinical inclusion
criteria (CIC-DN) or biopsy proof (BP-DN). Additionally, it assessed if the prevalence of the protective genotype changes with
diabetes duration and time on hemodialysis and if this occurs in association with serum carnosinase (CN-1) activity. Whereas
the distribution of the (CTG)5 homozygous genotype in the no-DN and CIC-DN patients was comparable, a lower frequency
was found in the BP-DN patients, particularly in females. We observed a signiﬁcant trend towards high frequencies of the
(CTG)5 homozygous genotype with increased time on dialysis. This was also observed for diabetes duration but only reached
signiﬁcance when both (CTG)5 homo- and heterozygous patients were included. CN-1 activity negatively correlated with time
on hemodialysis and was lower in (CTG)5 homozygous patients. The latter remained signiﬁcant in female subjects after gender
stratiﬁcation. We conﬁrm the association between the CNDP1 genotype and DN to be likely gender-speciﬁc. Although our data
also suggest that (CTG)5 homozygous patients may have a survival advantage on dialysis and in diabetes, this hypothesis needs
to be conﬁrmed in a prospective cohort study.
1. Introduction
Diabetic nephropathy (DN) occurs in approximately 40% of
patients with type 1 and type 2 diabetes [1] and is the leading
cause of end-stage renal disease (ESRD) [2]. Compelling
evidence has shown that susceptibility to DN is genetically
determined [3, 4]. Amongst the reported linkage studies,
there seems to be consistency in the linkage between human
chromosome 18q22.3-q23 and DN [4–7]; linkage to the DN
trait on chromosomes 7q21.3, 10p15.3, and 14q23.1 has also
been reported [7]. Linkage with 18q22.3 was observed in
populations of diﬀerent ethnicities, for example, American
Indians [8], Afro-Americans [9], and Caucasians [5].
Janssen et al. initially postulated that the CNDP1 gene
on chromosome 18q22.3-q23, encoding serum carnosinase
(CN-1), is a susceptibility gene for DN in type 2 diabetes
mellitus (T2DM) patients [10]. It was found that T2DM
patients homozygous for the CNDP1 (CTG)5 allele are less
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frequently aﬀected by DN compared to T2DM patients
with other CNDP1 genotypes [10]. The prevalence of the
(CTG)5 allele strongly varies with diﬀerent ethnicities.
While homozygosity for the (CTG)5 allele is more frequent
in the European population (38.6% in healthy controls and
29.3% in diabetic patients with ESRD) [11], this genotype
seems to be much more rare in the Asian population with a
high prevalence of DN [12, 13]. It has also been reported that
the association between the CNDP1 genotype and DN is sex-
speciﬁc and independent of susceptibility to T2DM [14].
Since most patients with T2DM are not formally evalu-
ated with a renal biopsy, the diagnosis of DN is based on
clinical criteria, for example, persistent macroalbuminuria
on at least 2 independent occasions (albumin excretion
rate > 300mg/d or >200mg/l or ACR (albumin/creatinine
ratio) > 300mg/g). Yet, biopsy-based retrospective evalua-
tions of the prevalence of nondiabetic renal disease (NDRD)
in T2DM patients revealed a high percentage of patients
having NDRD without evidence of concurrent DN [15, 16].
Although the predictive value of clinical criteria for DN in
T2DM patients can be improved by the presence of prolifer-
ative retinopathy [17, 18], genetic studies that use clinical
inclusion criteria (CIC) for group allocation still bear the risk
of wrongly assigning patients to the DN group. In the present
study, we assessed if the association between CNDP1 and DN
is still observed when applying CIC or biopsy-proven dia-
betic nephropathy (BP-DN) and, if so, whether this is only
observed in female T2DM patients. Since also an association
between the CNDP1 (CTG)5 homozygous genotype and car-
diovascular mortality has been reported to be sex-speciﬁc
[19], we also assessed if the prevalence of this genotype
changes with diabetes duration and time on dialysis. Since
T2DM patients on dialysis have a high mortality risk, it
would be expected that the proportion of CNDP1 (CTG)5
homozygous patients would decrease with time on dialysis,
particularly in females.
2. Materials and Methods
2.1. Patients. Patients were recruited between 2011 and 2014
from the Fifth Medical Clinic and Dialysis Unit at the Uni-
versity Medical Centre Mannheim and diﬀerent nephrology
practices in proximity (Centre for Renal Disease, Weinheim,
Lindenfels, Viernheim; Nephrocare Ludwigshafen GmbH;
KfH Nierenzentrum, Ludwigshafen; Nephrology Practice
Frankenthal, Bad Dürkheim, Lampertheim). After screening
of clinical records (n = 384) and patients with a biopsy-
proven renal diagnosis (n = 52), a total of 436 patients were
deemed to be eligible for this study. Due to the retrospective
nature of this study, indications for renal biopsies were not
uniform and the histological evaluation was undertaken by
diﬀerent pathologists. Out of the 436 initially selected
patients, 66 were excluded because of incomplete clinical
data or missing informed consent. The remaining patients
(n = 370) were allocated to 5 diﬀerent groups, that is, 130
T2DM patients without DN (no-DN), 108 T2DM patients
with CIC-DN, 30 T2DM patients with BP-DN, 80 patients
with CIC nondiabetic renal disease (CIC-NDRD), and
22 patients with biopsy-proven nondiabetic renal disease
(BP-NDRD) (Figure 1). Patients without renal biopsy mate-
rial were allocated on the basis of clinical criteria as speciﬁed
below, whereas patients with renal biopsy material were
allocated either to the BP-DN or to the BP-NDRD group.
The ethnicity distributions in the no-DN and BP-DN groups
were broadly comparable (no-DN: 75% from Germany,
12.5% from Turkey; BP-DN: 70% from Germany, 17%
from Turkey).
Inclusion criteria for clinical diagnosis of DN were as fol-
lows: persistent macroalbuminuria on at least 2 independent
occasions (albumin excretion rate > 300mg/d or >200mg/l
or ACR (albumin/creatinine ratio) > 300mg/g) in combi-
nation with the diagnosis of diabetic retinopathy (DR)
(all severity degrees were allowed). This combination was
obligatory to reduce the possibility that cases with protein-
uria due to renal disease other than DN (NDRD) were
included [20]. Anuric patients with a history of macroalbu-
minuria were included. Exclusion criteria were urinary tract
infection or fever at the time of urine investigation,
documented renal disease other than DN, and a history of
kidney transplantation.
T2DM patients without DN (=control group) fulﬁlled
the following criteria: diabetes duration of at least 15 years
accompanied by normoalbuminuria on at least two indepen-
dent occasions (albumin excretion rate < 30mg/d or <20mg/l
or ACR< 30mg/g). Since approximately 80% of the diabetic
patients in this group were on ACE inhibitors or AT1
blockers, false-negative results based on albuminuria could
not be excluded. However, to minimize the possibility of
DN patients in the control group, only the normoalbuminu-
ric patients with no or mild nonproliferate DR were included
since the presence of nephropathy without signiﬁcant DR
is rare [18, 21, 22]. Diabetes mellitus was deﬁned by a
documented history of diabetes or a fasting blood glucose
of ≥7.0mmol/l (126mg/dl), a casual plasma glucose level
of ≥11.1mmol/l (200mg/dl), or a HbA1c level of ≥6.5%.
Nondiabetic patients with ESRD were included in the
CIC-NDRD group (n = 80) after screening of patient records
and medications along with laboratory testing for plasma
glucose or HbA1c levels to exclude diabetes.
Out of the whole cohort, 175 patients were on hemo-
dialysis including 90 diabetic patients and 85 NDRD
patients. Patients were dialyzed using a blood ﬂow rate of
200–300ml/min and a dialysate ﬂow rate of approximately
500ml/min.
Estimated GFR was calculated based on the MDRD
formula [23]. Serum was used to measure CN-1 activity
and concentration. Genotyping was performed on EDTA
blood. All samples were stored at −20°C until use. The study
protocol was approved by the local ethics committee, and all
patients gave written informed consent prior to the study
enrollment (no. 0193/2001).
2.2. Genotyping. Genomic DNA was isolated from whole
blood using the Genomic DNA isolation kit (Promega,
Mannheim, Germany) according to the manufacturer’s
instruction and stored at −20°C until use. A 167-base pair
fragment spanning the (CTG)n polymorphism of CNDP1
was ampliﬁed by standard PCRmethods using a ﬂuorescence
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labeled forward primer (5′FAM-AGGCAGCTGTGTGAGG
TAAC-3′) and an unlabeled reverse primer (5′-GGGTGAG
GAGAACATGCC-3′), respectively. Genotyping was perfor-
med by means of fragment analysis on an ABI 310 sequenc-
ing platform (ABI PRISM DNA analyzer 3100).
2.3. CN-1 Activity Assay. CN-1 activity was assayed based on
the method described by Teufel et al. [24].
2.4. Statistical Analysis. Quantitative data are depicted as
median with corresponding 25th and 75th percentiles (inter-
quartile range) or, when appropriate, as mean ± SEM. Stu-
dent’s t-test was carried out for comparison of continuous
variables. Qualitative data were analyzed using the χ2 test.
For pairwise comparisons, frequency tables were partitioned
into respective 2× 2 subtables. The signiﬁcance level was
corrected using the Bonferroni method based on the number
of planned comparisons. Univariate and multivariate logistic
regression analyses were performed to examine predictors
of biopsy-proven diabetic nephropathy. Variables with a
P value of <0.25 in the univariate analysis were included
into a full-model multivariate analysis. To compare frequen-
cies among groups, which have an ordering, the χ2 test for
trend (Cochran-Armitage test for trend) was carried out.
Time on hemodialysis was logarithmically transformed
before the correlation analysis because of its skewed distribu-
tion. The signiﬁcance level α was deﬁned as 0.05. Statistical
analyses were performed with GraphPad Prism 6.0 (Graph-
Pad Software, Inc., La Jolla, California) and Microsoft
Excel/XLSTAT 19.01 (Addinsoft, New York, USA).
3. Results
3.1. Patient Characteristics. Demographic and clinical char-
acteristics of all studied individuals are presented in Table 1.
Signiﬁcantly more male patients (64%) were recruited in the
CIC-DN group (males: n = 69, females: n = 39) as compared
to the no-DN group (50%) (males: n = 65, females: n = 65).
Gender distribution in the other groups resembled the CIC-
DN group (CIC-NDRD: 61% males, BP-DN: 70% males
and BP-NDRD: 64% males). BP-NDRD patients were diag-
nosed with hypertensive nephrosclerosis, IgA nephropathy,
lupus nephritis, or other categories of glomerulonephritis
(e.g., granulomatosis with polyangiitis and minimal change
GN). Irrespective of subgroup analyses, the distribution of
the most prevalent ethnicities was comparable in the no-DN
and BP-DN groups as determined by means of χ2 test. Also,
the frequency of (CTG)5 homozygosity did not diﬀer between
the two major ethnicities, German and Turkish.
It should be noted that in the group of BP-DN,
DM duration was shorter (time from DM diagnosis: 14
(9–20) years versus 21.0 (15–29) years, BP-DN versus CIC-
DN) with more severe hyperglycemia and albuminuria
(HbA1c: 7.6 (6.7–8.8) % versus 7.3 (6.8–8.2) %, albuminuria:
2070 (337–3290) mg/l versus 644 (327–2110) mg/l, BP-DN
versus CIC-DN).
3.2. Association of the CNDP1 (CTG)5 Homozygous Genotype
with Diabetic Nephropathy. If diagnosis of DN was based on
CIC alone, the frequency of the homozygous (CTG)5 geno-
type did not signiﬁcantly diﬀer between the no-DN and
CIC-DN groups (Figure 2(a), 36% versus 38%). The fre-
quency of the protective genotype dropped to 17% when
biopsy-proven DN was considered only (36% versus 17%;
no-DN versus BP-DN, P < 0 05, NS after Bonferroni correc-
tion) (Figure 2(a)).
To conﬁrm the previous ﬁndings of the sex-speciﬁc asso-
ciation between DN and the homozygous (CTG)5 genotype,
patients were stratiﬁed according to gender. In male patients,
neither CIC-DN nor BP-DN was associated with (CTG)5
homozygosity when compared to no-DN (no-DN: 34%,
CIC-DN: 42%, BP-DN: 24%) (Figure 2(b)). Although the
436 patients included
66 missing data or no informed consent
DRDN201NDhtiwMD2T831NDtuohtiwMD2T031
108 CIC‒DN 30 BP‒DN 80 CIC‒NDRD 22 BP‒NDRD
Inclusion criteria
(i) Normoalbuminuria
T2DM duration > 15 years















Figure 1: Flow diagram for patient recruitment and group allocation. DN: diabetic nephropathy, NDRD: nondiabetic renal disease,
NPDR: nonproliferative diabetic retinopathy, CIC: clinical inclusion criteria, BP: biopsy-proven, DR: diabetic retinopathy, ESRD: end-stage
renal disease.
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homozygous (CTG)5 genotype was less frequent in both
the female CIC-DN and the female BP-DN groups as
compared to the no-DN group, this diﬀerence was only
signiﬁcant for BP-DN (38% versus 0%, no-DN versus
BP-DN, P < 0 05, signiﬁcant after Bonferroni correction)
(Figure 2(c)).
To conﬁrm that (CTG)5 homozygosity is an inde-
pendent, negative predictor for biopsy-proven diabetic
nephropathy, multivariate logistic regression analysis was
performed (Table 2). Seven diabetes-associated factors
were selected as independent variables (age, BMI, diabetes
duration, HbA1c, male sex, systolic blood pressure, and
(CTG)5 homozygosity). All variables except BMI showed
a P value below 0.25 in univariate analysis and were con-
sequently included in the multivariate model. The Hosmer-
Lemeshow test demonstrated an excellent goodness of ﬁt
(χ2 = 3949, P = 0 862) of the resulting multivariate model.
The area under the receiver operating characteristic curve
(ROC-AUC) further indicated adequate discrimination
(AUC=0.797).
The (CTG)5 homozygous genotype was signiﬁcantly
associated with biopsy-proven nephropathy in both uni-
variate (OR=0.353, P = 0 047) and multivariate analyses
(OR=0.307, P = 0 046) and, as such, identiﬁed as an indepen-
dent protective factor. Interestingly, signiﬁcance was reached
despite themarkedly lower number of cases (n = 30) generally
Table 1: Demographic and clinical data of all patients.
No-DN CIC-DN BP-DN CIC-NDRD BP-NDRD
N 130 108 30 80 22
Demographic characteristics
Male sex—n (%) 65 (50) 69 (64) 21 (70) 49 (61) 14 (64)
Age—year 71 (63–75) 71 (62–76) 61 (57–69) 61 (48–74) 61 (55–78)
Clinical characteristics
Body mass index—kg/m2 31.1 (28–35) 29.8 (27–35) 29.9 (25–35) 24.5 (21–27) 27 (24–32)
Hypertension
Number of AHM 3 (2–3) 3 (2–4) 3 (2–5) 3 (1.5–4) 2 (2–4)
Blood pressure—mmHg
Systolic 129 (120–140) 135 (120–156) 140 (130–150) 135 (120–145) 140 (128–153)
Diastolic 70 (66–80) 70 (60–80) 75 (70–80) 70 (60–80) 70 (64–80)
Diabetes mellitus
Time from diagnosis—year 16 (13–20) 21 (15–29) 14 (9–20) — —
HbA1c—% 7.0 (6.4–8.1) 7.3 (6.8–8.2) 7.6 (6.7–8.8) 5.6 (5.4–5.7) 5.6 (5.1–6.2)
Kidney function
Creatinine—mg/dl 0.9 (0.8–1.1) 6.3 (3.7–8.8) 5.7 (3.0–7.3) 9.7 (7.5–11.5) 3.4 (1.7–5.0)
eGFR—ml/min 73 (61–87) 9 (6–16) 10 (6–20) 5 (4–8) 15 (8–37)
Hemodialysis—n (%) 0 (0) 83 (75) 18 (60) 85 (100) 8 (36)
HD duration—months∗ 0 (0–0) 26 (1–69) 3 (0–30) 56 (28–100) 0 (0–0.3)
Albuminuria—mg/l 9 (5–16) 644 (327–2110) 2070 (337–3290) 470 (261–1587) 556 (189–1308)
Retinopathy (DR)—n (%)
No DR 107 (82) 1 (0) 6 (20) — —
NPDR 23 (18) 68 (63) 11 (37) — —
Proliferative DR — 17 (16) 4 (13) — —
Maculopathy — 8 (7) 3 (10) — —
Laser therapy — 13 (12) 3 (10) — —
Polyneuropathy—n (%) 54 (42) 56 (52) 17 (57) — —
History—n (%)
Coronary heart disease 42 (32) 74 (69) 11 (37) 24 (30) 6 (22)
Cardiovascular event 20 (15) 42 (39) 7 (23) 14 (18) 5 (23)
Arterial occlusive disease 24 (18) 56 (52) 11 (37) 17 (21) 3 (14)
Stroke 19 (15) 28 (26) 6 (20) 8 (10) 2 (9)
Statin 86 (66) 79 (73) 19 (63) 28 (35) 10 (45)
Homozygous CTG5—n (%) 47 (36) 41 (38) 5 (17) 32 (40) 7 (32)
∗Patients on hemodialysis only. Categorical data are represented as numbers (%) and continuous data as median with corresponding 25th and 75th percentiles
(IQR). AHM: antihypertensive medication; eGFR: estimated glomerular ﬁltration rate; HD: hemodialysis; DR: diabetic retinopathy; NPDR: nonproliferative
diabetic retinopathy.
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believed to be necessary for obtaining suﬃcient power (i.e.,
n = 10/independent variable). In the multivariate model,
systolic blood pressure (OR=1.024, P = 0 045) was posi-
tively and age (OR=0.931, P = 0 007) and diabetes duration
(OR=0.895, P = 0 025) were negatively associated with
biopsy-proven nephropathy, respectively.
3.3. CNDP1Genotype Distribution over Time onHemodialysis
and Diabetes Duration. The CNDP1 genotype distribution
(CNDP1 (CTG)5 homozygous—versus all other CNDP1
genotypes) was tested in 175 patients on hemodialysis,
including 90 patients with DN according to CIC and/or


















































































































































































P < 0.05 
(c)
Figure 2: CNDP1 (CTG)n genotype distribution in T2DM patients. Genotype distribution is depicted as homozygosity for the (CTG)5 allele
(10 leucine) versus all other genotypes (≥11 leucine). Planned comparisons were carried out between T2DM patients without DN and with
either CIC- or BP-deﬁned nephropathy. (a) No signiﬁcant diﬀerence in genotype distribution was observed between T2DM patients with DN
and without DN when applying CIC. The frequency of patients homozygous for the (CTG)5 allele decreased when BP-DN was considered.
However, this diﬀerence did not hold after Bonferroni correction. ((b) and (c)) Gender stratiﬁcation ((b) male patients, (c) female patients)
showed no signiﬁcant diﬀerence in the frequency of homozygosity for the CNDP1 (CTG)5 allele between T2DM with and without DN when
applying CIC. When DN was conﬁrmed through biopsy, however, the frequency of CNDP1 (CTG)5 homozygosity signiﬁcantly decreased in
female T2DM patients, which remained signiﬁcant after Bonferroni adjustment.
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on the basis of hemodialysis duration, that is, time on
dialysis: <30 months (n = 60), between 30 and 100 months
(n = 76) and >100 months (n = 39). To assess the frequen-
cies over time on hemodialysis and diabetes duration, the
χ2 test for trend was carried out.
The frequency of the (CTG)5 homozygous genotype sig-
niﬁcantly increased with time on hemodialysis (<30 months:
33%, 30–100 months: 40%, >100 months: 49%, P < 0 05)
(Figure 3(a)), while gender distribution was approximately
equal in the groups. The association of the (CTG)5
homozygous genotype with time on hemodialysis was
not signiﬁcant in the subgroup analyses after gender
stratiﬁcation (contingency tables not shown).
Although the frequency of the homozygous CNDP1
(CTG)5 genotype uniformly increased with diabetes dura-
tion, this trend did not reach statistical signiﬁcance (<10
years: 27%, 10–15 years: 34%, 16–20 years: 37%, >20 years:
42%, P = 0 17) (Figure 3(b)). However, if patients with a
heterozygous CNDP1 (CTG)5 genotype were included
(i.e., patients with at least one (CTG)5 allele), there was
a clear, signiﬁcant trend towards high frequencies with
increasing diabetes duration (<10 years: 64%, 10–15 years:
75%, 16–20 years: 87%, >20 years: 90%, P < 0 01)
(Figure 3(c)).
3.4. CN-1 Activities in Hemodialysis Patients. Because serum
carnosinase (CN-1) activity correlates with CNDP1 (CTG)n
genotypes, that is, CN-1 activity is in general lower in indi-
viduals with less CTG copies, we also cross-sectionally
assessed if serum CN-1 activity changes with time on dialysis.
In line with the increased frequency of the homozygous
CNDP1 (CTG)5 genotype in the groups of patients with a
long history of hemodialysis, a signiﬁcant negative correla-
tion between serum CN-1 activity and log-transformed
hemodialysis duration was found in all patients (r = −0 33;
P < 0 0001, Figure 4(a)), T2DM patients only (r = −0 034,
P = 0 0006, Figure 4(b)), and nondiabetic hemodialysis
patients (r = −0 031, P = 0 004, Figure 4(c)).
To delineate if the CNDP1 genotype is relevant for
CN-1 activities in hemodialysis patients, patients on
hemodialysis were stratiﬁed on the basis of homozygosity
for the (CTG)5 allele. Out of 174 subjects, the 65 patients
carrying the homozygous CNDP1 (CTG)5 genotype showed
a signiﬁcantly lower serum CN-1 activity compared to
patients with other genotypes (Figure 5(a), P < 0 01).
This remained signiﬁcant in female (Figure 5(c), P < 0 05),
but not in male (Figure 5(b), P = 0 07) patients after
gender stratiﬁcation.
4. Discussion
This study examined whether the protection against DN
aﬀorded by the homozygous CNDP1 (CTG)5 genotype is still
observed when applying clinical inclusion criteria or biopsy
ﬁndings only and if the prevalence of the protective genotype
changes in situations of increased cardiovascular mortality.
Our results demonstrate that the frequency of the homozy-
gous CNDP1 (CTG)5 genotype in the group of patients with
biopsy-proven DN is signiﬁcantly lower as compared to the
groups of patients with no DN or with other biopsy-proven
nephropathies. Our study also indicates that the frequency
of homozygous CNDP1 (CTG)5 genotype tends to be higher
in patients with a longer duration of hemodialysis, particu-
larly in female patients. An analogous increase was detected
for patients carrying at least one (CTG)5 allele stratiﬁed for
diabetes duration.
CIC for group allocations in DN studies bears the risk of
wrongly assigning patients to the DN group as up to 20–50%
of diabetic patients with albuminuria develop NDRDwithout
concurrent DN [25, 26]. Although the presence of diabetic
retinopathy (DR) is helpful for the prediction of DN [27]
and thus improves the validity of group allocation, still DR
may be absent in up to 50% of DN patients [28, 29]. Contro-
versial studies reporting on genetic susceptibility loci for DN,
including those for the CNDP1 (CTG)n polymorphism,
might partly underlie this problem.
The use of large cohorts from diﬀerent consortia and sub-
sequent meta-analysis of data obtained from genome-wide
association studies (GWAS) may partly overcome this prob-
lem as the proportion of wrongly allocated patients might be
outnumbered by the large number of studied patients. The
GWAS approach has been successfully utilized in newer
studies conﬁrming susceptibility loci for declining glome-
rular ﬁltration rate (eGFR) or albuminuria [30–32]. The
CNDP1 locus, a postulated DN susceptibility locus found
by positional cloning [5] and case control studies [10], has
Table 2: Summary of logistic regression analysis of variables predicting biopsy-proven diabetic nephropathy (male and female, n = 160).
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age (years) 0.920 0.881–0.961 <0.001 0.931 0.883–0.980 0.007
BMI (kg/m2) 0.980 0.922–1.041 0.513 — — —
Diabetes duration (years) 0.886 0.813–0.966 0.006 0.895 0.812–0.986 0.025
HbA1c (%) 1.308 1.020–1.678 0.034 1.169 0.844–1.619 0.348
Male sex 2.333 0.994–5.477 0.052 1.957 0.748–5.124 0.171
SBP (mmHg) 1.021 1.000–1.042 0.052 1.024 1.001–1.047 0.045
CTG5 homozygosity 0.353 0.127–0.984 0.047 0.307 0.096–0.980 0.046
Area under the ROC curve (AUC) = 0.797, P = 0 862 for Hosmer-Lemeshow test. BMI: body mass index; SBP: systolic blood pressure.
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never been reported to be linked to DN in a GWAS approach,
despite the fact that other genetic studies [11, 14, 33, 34]
including a meta-analysis on 4546 DN, 7994 diabetes melli-
tus (DM), and 1826 healthy subjects [35] have conﬁrmed
an association between the CNDP1 (CTG)n polymorphism
and DN in T2DM patients. Signiﬁcance further increased
in these studies if more stringent CIC for DN, for example,
the presence of proliferative DR and a longer duration of
T2DM, were considered [11].
In our study, the association between theprotective homo-
zygous CNDP1 (CTG)5 genotype and DN was restricted to
biopsy-proven DN and only signiﬁcant in female patients
using the χ2 test. Multivariate logistic regression subsequently





































































































































































P < 0.01 
(c)
Figure 3: The CNDP1 (CTG)5 genotype distribution is changed with time on dialysis and diabetes duration. To assess if the frequencies
change over time, the χ2 test for trend (Cochran-Armitage test for trend) was carried out. (a) The frequency of the homozygous CNDP1
(CTG)5 genotype (10 leucine) signiﬁcantly increased with time on hemodialysis. ((b) and (c)) Although the observed frequency of the
homozygous (b) CNDP1 (CTG)5 genotype uniformly increased with diabetes duration, this trend did not reach statistical signiﬁcance. Yet,
if patients with a heterozygous (c) CNDP1 (CTG)5 genotype (one 5 allele) were included as well, a signiﬁcant trend towards high
frequencies with increasing diabetes duration was found. N.S.: not signiﬁcant.
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factor for biopsy-proven DN with an odds ratio of ap-
proximately 0.3. The negative association of age and diabetes
duration with biopsy-proven DN in this analysis may be
explained by the fact that in older diabetic patients, a renal
biopsy is often waived due to the lack of consequence.
The frequencies of the homozygous CNDP1 (CTG)5
genotype in the no-DN and BP-NDRD groups were com-
parable, suggesting that this genotype does not aﬀord protec-
tion against NDRD. Nonetheless, it would be prudent to be
cautious with this assumption as other studies have
suggested that this genotype also aﬀords protection against
other chronic kidney diseases (CKD), for example, glomeru-
lonephritis but not tubulointerstitial nephritis [36]. In this
light, the paradox between CIC-DN and BP-DN might be
due to the fact that patients with NDRD were falsely included
in the CIC-DN group, underscoring that clinical criteria do
not provide a suﬃcient certainty for the diagnosis of DN in
T2DM patients. It is important to note that patients in the
BP-DN group had a shorter DM duration and displayed
more severe hyperglycemia and albuminuria as compared
to the CIC-DN group. Because of this relatively atypical
DN course, these patients required a biopsy to clarify the
actual underlying renal disease. Whether the change in
CNDP1 genotype distribution between CIC-DN and BP-DN
underlies the severity of disease per se is unknown so far
and cannot be excluded.
Our data are in agreement with a previous publication
showing that the association of CNDP1 and DN is most likely
sex-speciﬁc [14]. Although also in males of the BP-DN group
the frequency of the (CTG)5 homozygous genotype was
lower as compared to the no-DN group, it was only signiﬁ-
cantly decreased in female BP-DN patients. The sex-speciﬁc
protection of CNDP1 is generally explained by higher serum
CN-1 activities in females [14].
In keeping with the recently published prospective study
that the CNDP1 genotype may impart a cardiovascular mor-
tality risk in female, but not in male T2DM patients [19], we
investigated whether genotype distribution changes with
time on dialysis or diabetes duration. Since both of the latter
variables are associated with an increased (cardiovascular)
mortality risk, it would be expected based on the above study
that the frequency of the homozygous CNDP1 (CTG)5 geno-
type would decrease rather than increase in patients with a
long history of hemodialysis. By contrast, our data show that
the frequency of the homozygous CNDP1 (CTG)5 genotype
was signiﬁcantly increased in patients with a long history
of hemodialysis. This diﬀerence remained in both males
and females although it was not statistically signiﬁcant,
which is likely explained by the small sample size of the
subgroup analysis. Similar ﬁndings were also observed
with respect to a longstanding diabetes duration when all
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(c)
Figure 4: CN-1 activities decrease with time on dialysis. (a) Serum CN-1 activity was assessed in 175 hemodialysis patients and plotted
against the log-transformed duration since hemodialysis was initiated. A signiﬁcant correlation between serum CN-1 activity and log-
transformed hemodialysis duration was found in all patients. ((b) and (c)) After stratiﬁcation in T2DM (b) and other causes of renal
failure (c), the correlation remained signiﬁcant. HD: hemodialysis.
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Although our ﬁndings suggest that in patients on hemodi-
alysis and in diabetic patients the CNDP1 (CTG)5 geno-
type may not impart an additional mortality risk, it
should be underscored that the small group sizes and the
cross-sectional design of this study impede drawing ﬁrm
conclusions, in particular since a considerable number of
hemodialysis patients were not diabetic. Nonetheless, these
ﬁndings suggest that in patients on hemodialysis and in
diabetes, the CNDP1 (CTG)5 genotype may not impart
an additional mortality risk.
Serum CN-1 concentrations and activities are in part
determined by (CTG)n polymorphism [10, 37]. Since this
repeat is located in the hydrophobic part of the CN-1 signal
peptide and is essential for the translocation of CN-1 protein
during secretion, it is believed that the shorter (CTG)5
variant is less eﬃciently secreted [37]. In line with an
increased frequency of the homozygous CNDP1 (CTG)5
genotype in patients with a long history of hemodialysis,
CN-1 activities were reduced. This reduction is not due
to the loss of protein through hemoﬁltration since serum
CN-1 concentrations even increase proportionally to the
amount of ultraﬁltrate [38].
As discussed above, we acknowledge the relatively
small sample size as a major limitation of our study,
accounting for a limited statistical power regarding major
questions addressed. In addition, in contrast to a pro-
spective study design, no systematic biopsy strategy with
uniform indications and assigned nephropathologists could
be implemented. Other studies, however, demonstrated
that the histological classiﬁcation of DN based on glomer-
ulopathy shows a satisfying interobserver reproducibility


























































































































Figure 5: CN-1 activity correlates with CNDP1 genotype in hemodialysis patients. (a) CN-1 activity in (CTG)5 homozygous hemodialysis
patients is signiﬁcantly lower than that in patients carrying other genotypes. ((b) and (c)) After gender stratiﬁcation diﬀerences in CN-1
activity between the (CTG)5 homozygous, all other genotypes remained but only reached statistical signiﬁcance in females (c).
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procedure of patient allocation leading to limited group
selectivity. This holds true especially for the diabetic con-
trol group without DN, which is based only on clinical cri-
teria instead of a histological diagnosis. As 80% of these
patients were on ACE inhibitor or AT1-blocking drugs,
albuminuria alone was not a reliable parameter. Despite
the extension of the criteria by diabetes duration of >15
years and exclusion of patients which manifest retinopathy,
accidental assignment of patients with DN to this group is
not improbable.
In our eyes, the fact that this study still resulted in
signiﬁcant results in the light of these conceptual drawbacks
supports a particular strong association of our ﬁndings.
Our study supports the hypothesis that protection against
DN is indeed aﬀorded by the CNDP1 (CTG)5 genotype and
that this association mainly applies to female T2DM patients.
The restriction of this ﬁnding to the BP-DN group may be
attributed to false allocation of patients with other pro-
teinuric diseases to the CIC-DN group. In fact, 20–50% of
diabetic patients with proteinuria display NDRD without
concurrent DN [25, 26]. Our investigation also suggests that
(CTG)5 homozygous hemodialysis patients and patients with
diabetes carrying at least one (CTG)5 allele might have a
survival beneﬁt as compared to other genotypes. These
ﬁndings warrant further conformational studies, ideally
with a prospective longitudinal design.
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